Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art
- PMID: 26877601
- PMCID: PMC4726669
- DOI: 10.3748/wjg.v22.i6.1935
Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art
Abstract
In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma (HCC). One such combined strategy is based on the combination of the percutaneous approach, such as radiofrequency ablation (RFA), and the intra-arterial locoregional approach, such as trans-arterial chemoembolization (TACE). Several types of evidence have supported the feasibility and benefit of combined therapy, despite some studies reporting conflicting results and outcomes. The aim of this review was to explain the technical aspects of different combined treatments and to comprehensively analyze and compare the clinical efficacy and safety of this combined treatment option and monotherapy, either as TACE or RFA alone, in order to provide clinicians with an unbiased opinion and valuable information. Based on a literature review and our experience, combined treatment seems to be a safe and effective option in the treatment of patients with early/intermediate HCC when surgical resection is not feasible; furthermore, this approach provides better results than RFA and TACE alone for the treatment of large HCC, defined as those exceeding 3 cm in size. It can also expand the indication for RFA to previously contraindicated "complex cases", with increased risk of thermal ablation related complications due to tumor location, or to "complex patients" with high bleeding risk.
Keywords: Ablation; Chemoembolization; Combined treatment; Hepatocellular carcinoma; Microwave.
Figures


Similar articles
-
Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis.Hepatogastroenterology. 2015 May;62(139):710-4. Hepatogastroenterology. 2015. PMID: 26897959 Review.
-
Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077. J Gastroenterol Hepatol. 2016. PMID: 26259976
-
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?Eur J Radiol. 2019 May;114:32-37. doi: 10.1016/j.ejrad.2019.02.030. Epub 2019 Feb 23. Eur J Radiol. 2019. PMID: 31005173
-
Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas.World J Gastroenterol. 2013 Jul 14;19(26):4192-9. doi: 10.3748/wjg.v19.i26.4192. World J Gastroenterol. 2013. PMID: 23864783 Free PMC article.
-
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327. World J Gastroenterol. 2015. PMID: 26420959 Free PMC article. Review.
Cited by
-
Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions.World J Gastroenterol. 2019 Aug 28;25(32):4614-4628. doi: 10.3748/wjg.v25.i32.4614. World J Gastroenterol. 2019. PMID: 31528090 Free PMC article. Review.
-
Long-term outcome of novel combined surgical-injection treatment (COSIT) for large hepatocellular carcinoma: Stage 2A IDEAL prospective case series.Ann Med Surg (Lond). 2021 Nov 24;72:103098. doi: 10.1016/j.amsu.2021.103098. eCollection 2021 Dec. Ann Med Surg (Lond). 2021. PMID: 34888043 Free PMC article.
-
"Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications?Life (Basel). 2020 Sep 6;10(9):180. doi: 10.3390/life10090180. Life (Basel). 2020. PMID: 32899925 Free PMC article. Review.
-
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.Dig Dis Sci. 2022 Jul;67(7):3455-3463. doi: 10.1007/s10620-021-07156-2. Epub 2021 Jul 23. Dig Dis Sci. 2022. PMID: 34297268 Clinical Trial.
-
Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.J Hepatocell Carcinoma. 2021 Jun 21;8:625-644. doi: 10.2147/JHC.S298709. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 34189133 Free PMC article. Review.
References
-
- European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. - PubMed
-
- Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405. - PubMed
-
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52. - PMC - PubMed
-
- Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116:3638–3644. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous